ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2022

Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic.

Aurora Zanghì et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.